- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
NovaBridge Biosciences (NBP)
Track today's live NovaBridge (NBP) share price, performance and key data on this page with our current NASDAQ:NBP stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the NovaBridge share price on the NASDAQ exchange. Use the dropdown to switch exchange for the NBP share price, head to our technical summary section, which provides analysis on NovaBridge share price buy/sell indicators using real-time data (or discuss the NovaBridge (NBP) stock price today with other investors in the NovaBridge NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:NBP share price (ISIN: US44975P1030) to enhance your trading decisions with our free investment tools and resources.
What Is the NovaBridge Biosciences Share Price Today?
The NovaBridge share price today is 1.010.
What Is the Stock Symbol for NovaBridge Biosciences
The stock symbol (or 'ticker') for NovaBridge Biosciences is "NBP."
What Stock Exchange Does NovaBridge Biosciences Trade On?
NovaBridge Biosciences is listed and trades on the NASDAQ stock exchange.
Is NovaBridge Biosciences a Good Stock to Buy?
Determining whether NovaBridge (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:NBP share price (ISIN: US44975P1030) to enhance your trading decisions with our free investment tools and resources.
What Is the NovaBridge Biosciences Share Price Today?
The NovaBridge share price today is 1.010.
What Is the Stock Symbol for NovaBridge Biosciences
The stock symbol (or 'ticker') for NovaBridge Biosciences is "NBP."
What Stock Exchange Does NovaBridge Biosciences Trade On?
NovaBridge Biosciences is listed and trades on the NASDAQ stock exchange.
Is NovaBridge Biosciences a Good Stock to Buy?
Determining whether NovaBridge (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.010
1.060
52 wk Range
1.010
5.190
Trading near 52-week Low
1/3
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.0101.060
52 wk Range
1.0105.190
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NBP Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
8.667
Upside
+758.09%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in oversold territory
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 8.667
(+758.09% Upside)
NovaBridge Biosciences Earnings Call Summary for Q2/2026
- NovaBridge ended Q2 2026 with $216M in cash and no debt, sufficient to fund givastomig through 2028 Phase III interim readout.
- Shares fell 8.59% to $1.81 despite positive pipeline updates; no revenue reported and analysts expected 12-cent loss per share.
- Givastomig received FDA Fast Track status in June, showing 75% response rate and 16.9-month median PFS in Phase I-B trial data.
- Company plans Phase III initiation for givastomig in Q4 2026 and Phase IIb study for VIS-101 ophthalmology asset in H2 2026.
- Management highlighted givastomig's simple infusion profile as competitive advantage in crowded Claudin 18.2 cancer treatment space.
Last Updated: 20/08/2026, 15:12
Read Full TranscriptEarnings
Latest Release
20/08/2026
EPS / Forecast
-0.16 / -0.12
Revenue / Forecast
-- / --
Compare NBP to Peers and Sector
Metrics to compare | NBP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNBPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.0x | −5.1x | −0.2x | |
PEG Ratio | 0.01 | −0.20 | 0.00 | |
Price/Book | 0.6x | 3.6x | 2.6x | |
Price / LTM Sales | - | 17.4x | 2.8x | |
Upside (Analyst Target) | - | 311.1% | 62.7% | |
Fair Value Upside | Unlock | 6.3% | 8.0% | Unlock |
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the NovaBridge (NASDAQ: NBP) Share Price Today?
The NovaBridge stock price today is 1.010 USD.
What Stock Exchange Does NovaBridge (NBP) Trade On?
NovaBridge is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for NovaBridge?
The stock symbol (also called a 'ticker') for NovaBridge is "NBP."
What Is the Current NovaBridge Market Capitalisation?
As of today, NovaBridge (NASDAQ: NBP) market cap is 117.160M USD.
What Is NovaBridge's (NBP) Earnings Per Share (TTM)?
The NovaBridge EPS is currently -1.04 (Trailing Twelve Months).
When Is the Next NovaBridge Earnings Date?
NovaBridge's next earnings report will be released on 12/11/2026.
Is NBP a Buy or Sell From a Technical Analyst Perspective?
Based on today's NovaBridge moving averages and other technical indicators, the daily buy/sell signal for NBP stock is Strong Sell.
How Many Times Has NovaBridge Stock Split?
NovaBridge has split 0 times. (See the NBP stock split history page for full effective split date and price information.)
What is the current trading status of NovaBridge (NASDAQ: NBP)?
As of 05/11/2026, NovaBridge (NBP) is trading at a share price of 1.010 USD, with a previous close of 1.010 USD. The stock has fluctuated within a day range of 1.010 USD to 1.060 USD, while its 52-week range spans from 1.010 USD to 5.190 USD.
What Is NovaBridge (NBP) Price Target According to Analysts?
The average 12-month price target for NovaBridge is 8.667 USD, with a high estimate of 9 USD and a low estimate of 8 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +758.09% Upside potential.
What Is the NBP Premarket Price?
NBP's last pre-market stock price is 1.050 USD. The pre-market share volume is 600.000, and the stock has decreased by 0.040, or 3.960%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.